Long-term Keytruda data show durable responses

Follow-up data from the Phase Ib KEYNOTE-001 study of Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) to treat advanced melanoma showed a three-year overall survival

Read the full 261 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE